Boundless Bio Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022
Selling, General & Admin	12.16	9.31
Research & Development	42.64	37.16
Operating Expenses	54.8	46.47
Operating Income	-54.8	-46.47
Other Expense / Income	-5.36	-0.57
Pretax Income	-49.43	-45.9
Net Income	-49.43	-45.9
Shares Outstanding (Basic)	1	1
Shares Outstanding (Diluted)	1	1
Shares Change	10.75%	-
EPS (Basic)	-40.65	-41.80
EPS (Diluted)	-40.65	-41.80
Free Cash Flow	-47.49	-40.66
Free Cash Flow Per Share	-39.05	-37.03
EBITDA	-46.12	-43.35
Depreciation & Amortization	3.32	2.55
EBIT	-49.43	-45.9

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).